4.5 Review

Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder

Journal

ACTA PAEDIATRICA
Volume 102, Issue 5, Pages 462-470

Publisher

WILEY
DOI: 10.1111/apa.12169

Keywords

Attention deficit/hyperactivity disorder; Autism spectrum disorder; Developmental disabilities; Mucopolysaccharidosis type III; Speech/language disorders

Categories

Funding

  1. Shire Human Genetic Therapies, Inc.
  2. Shire Human Genetic Therapies
  3. Genzyme
  4. BioMarin Pharmaceutical Inc.
  5. Actelion Pharmaceuticals

Ask authors/readers for more resources

Mucopolysaccharidosis III is a rare genetic disease characterized by progressive cognitive decline and severe hyperactivity that does not respond to stimulants. Somatic features are relatively mild. Patients are often initially misdiagnosed as having idiopathic developmental delay, attention deficit/hyperactivity disorder and/or autism spectrum disorders, putting them at risk for unnecessary testing and treatments. Conclusion Children with developmental or speech delay, especially those with a characteristic somatic feature or behavioural abnormalities, should be screened for MPS III.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available